PT - JOURNAL ARTICLE AU - Patel, Ashish AU - Gill, Dipender AU - Shungin, Dmitry AU - Mantzoros, Christos S. AU - Knudsen, Lotte Bjerre AU - Bowden, Jack AU - Burgess, Stephen TI - Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: application of <em>cis</em>-multivariable Mendelian randomization to <em>GLP1R</em> gene region AID - 10.1101/2023.07.20.23292958 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.20.23292958 4099 - http://medrxiv.org/content/early/2023/07/25/2023.07.20.23292958.short 4100 - http://medrxiv.org/content/early/2023/07/25/2023.07.20.23292958.full AB - Phenotypic heterogeneity at genomic loci encoding drug targets can be exploited by multivariable Mendelian randomization to provide insight on the pathways by which pharmacological interventions may affect disease risk. However, statistical inference in such investigations may be poor if overdispersion heterogeneity in measured genetic associations is unaccounted for. In this work, we first develop conditional F-statistics for dimension-reduced genetic associations that enable more accurate measurement of phenotypic heterogeneity. We then develop a novel extension for two-sample multivariable Mendelian randomization that accounts for overdispersion heterogeneity in dimension-reduced genetic associations. Our empirical focus is to use genetic variants in the GLP1R gene region to understand the mechanism by which GLP1R agonism affects coronary artery disease (CAD) risk. Colocalization analyses indicate that distinct variants in the GLP1R gene region are associated with body mass index and type 2 diabetes. Multivariable Mendelian randomization analyses that were corrected for overdispersion heterogeneity suggest that bodyweight lowering rather than type 2 diabetes liability lowering effects of GLP1R agonism are more likely contributing to reduced CAD risk. Tissue-specific analyses prioritised brain tissue as the most likely to be relevant for CAD risk, of the tissues considered. We hope the multivariable Mendelian randomization approach illustrated here is widely applicable to better understand mechanisms linking drug targets to diseases outcomes, and hence to guide drug development efforts.Competing Interest StatementD.G. and J.B. are part time employees of Novo Nordisk. D.S. and L.B.K. are full time employees of Novo Nordisk.Funding StatementS.B. was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). This research was funded by the United Kingdom Research and Innovation Medical Research Council (MC-UU-00002/7), and supported by the National Institute for Health Research Cambridge Biomedical Research Centre: BRC-1215-20014.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data that support the findings of this study are openly available from UK Biobank at http://www.nealelab.is/uk-biobank; the DIAMANTE consortium at https://kp4cd.org/node/169; the GIANT consortium at https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium; the Genotype-Tissue Expression (GTEx) project version 8 at https://gtexportal.org/home/; and the CARDIoGRAMplusC4D consortium at http://www.cardiogramplusc4d.org/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are openly available from UK Biobank at http://www.nealelab.is/uk-biobank; the DIAMANTE consortium at https://kp4cd.org/node/169; the GIANT consortium at https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium; the Genotype-Tissue Expression (GTEx) project version 8 at https://gtexportal.org/home/; and the CARDIoGRAMplusC4D consortium at http://www.cardiogramplusc4d.org/. http://www.nealelab.is/uk-biobank https://kp4cd.org/node/169 https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium https://gtexportal.org/home/ http://www.cardiogramplusc4d.org/